Recommendations for genetic testing to reduce the incidence of anthracycline‐induced cardiotoxicity
British Journal of Clinical Pharmacology2016Vol. 82(3), pp. 683–695
Citations Over TimeTop 1% of 2016 papers
Folefac Aminkeng, Colin J.D. Ross, Shahrad R. Rassekh, Soomi Hwang, Michael Rieder, Amit P. Bhavsar, Anne Smith, Shubhayan Sanatani, Karen A. Gelmon, Daniel Bernstein, Michael R. Hayden, Ursula Amstutz, Bruce Carleton
Abstract
Existing evidence demonstrates that genetic factors have the potential to improve the discrimination between individuals at higher and lower risk of ACT. Genetic testing may therefore support both patient care decisions and evidence development for an improved prevention of ACT.
Related Papers
- → Chemotherapy-induced cardiotoxicity in children(2017)84 cited
- → Genotyping the risk of anthracycline-induced cardiotoxicity(2007)79 cited
- [Cardiotoxicity of conservative treatment of solid tumors].(2012)
- Anthracycline-induced cardiotoxicity, a pathophysiology based approach for early detection and protective strategies(2012)